CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
Omalizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01781637
NCT01781637Phase 2Completed
CompareCT.gov

Phase 2 Study of Omalizumab in Oral Peanut Desensitization

Boston Children's Hospital·interventional·Posted Feb 1, 2013·Updated Feb 21, 2023

In Brief

A Phase 2 clinical trial evaluating Omalizumab and placebo for Peanut Allergy and Food Allergy. Completed, enrolled 36 participants across 4 sites.

Detailed Summary

The investigators will perform a double blind, placebo controlled clinical trial with Xolair (omalizumab) at four centers to safely and rapidly desensitize patients with severe peanut allergy. The investigators will determine if pretreatment with anti-IgE mAb (Xolair/omalizumab) can greatly reduce allergic reactions and allow for faster and safer desensitization.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeanut Allergy, Food Allergy
CountriesUnited States
CollaboratorsChildren's Hospital of Philadelphia, Stanford University, Ann & Robert H Lurie Children's Hospital of Chicago

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 1, 2013
Enrollment StartJan 1, 2013
Primary CompletionOct 1, 2015
Study CompletionMay 31, 2022
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.4 years ago

Interventions

Omalizumabdrug

subcutaneous injection

placebodrug

subcutaneous injection